1)Truelove SC, Richards WC. Biopsy studies in ulcerative colitis. Br Med J 1:1315-1318, 1956
2)Matts SG. The value of rectal biopsy in the diagnosis of ulcerative colitis. Q J Med 30:393-407, 1961
3)Dick AP, Holt LP, Dalton ER. Persistence of mucosal abnormality in ulcerative colitis. Gut 7:355-360, 1966
4)D'Haens G, Sandborn WJ, Feagan BG, et al. A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology 132:763-786, 2007
5)Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med 317:1625-1629, 1987
6)Laharie D, Filippi J, Roblin X, et al. Impact of mucosal healing on long-term outcomes in ulcerative colitis treated with infliximab:a multicenter experience. Aliment Pharmacol Ther 37:998-1004, 2013
7)Saigusa K, Matsuoka K, Sugimoto S, et al.Ulcerative colitis endoscopic index of severity is associated with long-term prognosis in ulcerative colitis patients treated with infliximab. Dig Endosc 28:665-670, 2016
8)Travis SPL, Schnell D, Krzeski P, et al. Developing an instrument to assess the endoscopic severity of ulcerative colitis:the Ulcerative Colitis Endoscopic Index of Severity(UCEIS). Gut 61:535-542, 2012
9)Ikeya K, Hanai H, Sugimoto K, et al. The Ulcerative Colitis Endoscopic Index of Severity more accurately reflects clinical outcomes and long-term prognosis than the Mayo endoscopic score. J Crohns Colitis 10:286-295, 2016
10)Bryant RV, Winer S, Travis SPL, et al. Systematic review:histological remission in inflammatory bowel disease. Is ‘complete' remission the new treatment paradigm? An IOIBD initiative. J Crohns Colitis 8:1582-1597, 2014
11)Riley SA, Mani V, Goodman MJ, et al. Microscopic activity in ulcerative colitis:what does it mean? Gut 32:174-178, 1991
12)Geboes K, Riddell R, Ost A, et al. A reproducible grading scale for histological assessment of inflammation in ulcerative colitis. Gut 47:404-409, 2000
13)Marchal-Bressenot A, Salleron J, Boulagnon-Rombi C, et al. Development and validation of the Nancy histological index for UC. Gut 66:43-49, 2017
14)Mosli MH, Feagan BG, Zou G, et al. Development and validation of a histological index for UC. Gut 66:50-58, 2017
15)Lang-Schwarz C, Angeloni M, Agaimy A, et al. Validation of the ‘inflammatory bowel disease-distribution, chronicity, activity[IBD-DCA]score' for ulcerative colitis and Crohn's disease. J Crohns Colitis 15:1621-1630, 2021
16)Gupta A, Yu A, Peyrin-Biroulet L, et al. Treat to target:the role of histologic healing in inflammatory bowel diseases:a systematic review and meta-analysis. Clin Gastroenterol Hepatol 19:1800-1813, 2021
17)味岡洋一,横山純二,本間照.炎症性腸疾患の内視鏡的重症度評価における病理組織学的所見の位置づけ—生検組織の炎症活動性評価の観点から.胃と腸 53:148-156, 2018
18)Tanaka M, Saito H, Kusumi T, et al. Biopsy pathology predicts patients with ulcerative colitis subsequently requiring surgery. Scand J Gastroenterol 37:200-205, 2002
19)Heatley RV, James PD. Eosinophils in the rectal mucosa. A simple method of predicting the outcome of ulcerative proctocolitis? Gut 20:787-791, 1979
20)Ozaki R, Kobayashi T, Okabayashi S, et al. Histological risk factors to predict clinical relapse in ulcerative colitis with endoscopically normal mucosa. J Crohns Colitis 12:1288-1294, 2018
21)安達世,荒川廣志,小山誠太,他.Mayo scoreによる潰瘍性大腸炎のmucosal healingと病理組織学的活動性との相関.Prog Dig Endosc 85:43-46, 2014
22)Christensen B, Hanauer SB, Erlich J, et al. Histologic normalization occurs in ulcerative colitis and is associated with improved clinical outcomes. Clin Gastroenterol Hepatol 15:1557-1564, 2017
23)田中正則.炎症性腸疾患の病理診断—鑑別診断と病期・重症度診断について.病理と臨 29:1071-1078, 2011